|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Labetalol#Structure]] |
| {{Labetalol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| ==Description==
| |
|
| |
| Labetalol hydrochloride tablets, USP are adrenergic receptor blocking agents that have both selective alpha1-adrenergic and nonselective beta-adrenergic receptor blocking actions in a single substance.
| |
|
| |
| Labetalol hydrochloride (HCl) is a racemate chemically designated as 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl) amino] ethyl] benzamide monohydrochloride, and it has the following structure:
| |
| {|
| |
| |-
| |
| |[[File:Labetalol07.jpg|thumb|800px]]
| |
| |-
| |
| |}
| |
| Labetalol HCl has the molecular formula C19H24N2O3•HCl and a molecular weight of 364.9. It has two asymmetric centers and therefore exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R, R´stereoisomer, makes up 25% of racemic labetalol.
| |
|
| |
| Labetalol HCl is a white or off-white crystalline powder, soluble in water.
| |
|
| |
| Labetalol hydrochloride tablets contain 100, 200, or 300 mg of labetalol HCl and are taken orally. The tablets also contain the inactive ingredients lactose monohydrate, corn starch, crospovidone, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, titanium dioxide and talc.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LABETALOL HYDROCHLORIDE TABLET, FILM COATED [WATSON LABORATORIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5b65a9b-6b8a-48a4-9c72-0e605bb309eb | publisher = | date = | accessdate = 5 February 2014 }}</ref>
| |
|
| |
|
| |
| ==References==
| |
|
| |
| {{Reflist|2}}
| |
|
| |
|
| [[Category:Beta blockers]] | | [[Category:Beta blockers]] |
|
| |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |